This report discusses the difference between antiphospholipid antibodies (aPL) as a predictor for first and recurrent ischemic stroke, whether or not concomitant systemic lupus erythematosus (SLE) increases aPL-associated risk, and the association of aPL with other neurological manifestations. The neurological manifestations covered in this report were selected because they are among the most common, including cognitive dysfunction, headache, multiple sclerosis and seizures/epilepsy. Recommendations are made regarding further research that is needed to clarify remaining uncertainties.
CerveraRPietteJCFontJ. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002; 46: 1019–1027.
2.
TrysbergENylenKRosengrenLE. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum2003; 48: 2881–2887.
HorstmanLLJyWBidotCJ. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation2009; 6: 3–3.
6.
UrbanusRTSiegerinkBRoestM. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol2009; 8: 998–1005.
7.
TohgiHTakahashiHKasiwayaMWatanabeKHayamaK. The anticardiolipin antibody in elderly Stroke patients: its effects on stroke types, recurrence and the coagulation-fibrinolysis system. Acta Neurol Scand1994; 90: 86–90.
8.
LevineSRBreyRLSawayaKL. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol1995; 38: 119–124.
9.
APASS. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology1997; 48: 91–94.
10.
ZielinskaJRyglewiczDWierzchoskaELechowiczWHierDBCzlonkiwskaA. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res1999; 21: 653–657.
11.
HeinzlefOAbuafNCohenAAmarencoP, French Study of Aortic Plaques in Stroke Group. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurology2001; 248: 373–379.
12.
TanneDD’OlhaberriagueLTrivediAMSalowich-PalmLSchyltzLRLevineSR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology2002; 21: 93–99.
13.
LevineSRBreyRLTilleyBC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA2004; 291: 576–584.
14.
TanasescuRTicmeanuMNicolauA. Anticardiolipin antibodies, recurrent stroke and vascular events: a prospective study on 210 patients. Rom J Inter Med2005; 43: 79–88.
15.
AvcinTCimazRSilvermanED. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics2008; 122: e1100–e1107.
16.
AvcinTBenselerSMTyrrellPN. A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum2008; 59: 206–213.
17.
AngeliniLRavelliACaporaliR. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics1994; 94: 500–503.
18.
CerveraRKhamashtaMAFontJ. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)2003; 82: 299–308.
19.
MikdashiJHandwergerBLangenbergPMillerMKittnerS. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke2007; 38: 281–285.
20.
TolozaSMUribeAGMcGwinGJr. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum2004; 50: 3947–3957.
21.
AkimotoTKobayashiSTamuraN. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology2005; 56: 601–609.
22.
HanlyJGHongCSmithSFiskJD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum1999; 42: 728–734.
23.
MenonSJameson-ShortallENewman Hall-CraggsSPChinnRIsenbergDA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum1999; 42: 735–741.
24.
McLaurinEYHollidaySLWilliamsPBreyRL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology2005; 64: 297–303.
25.
TomiettoPAnneseVD’agostiniS. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum2007; 57: 1461–1472.
26.
Mejia-RomeroRGarcia-CarrascoMGalarza-MaldonadoC. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol2008; 27: 891–897.
27.
HeinzlefOWeillBJohanetC. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry2002; 72: 647–649.
28.
Sastre-GarrigaJReverterJCFontJ. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol2001; 49: 408–411.
29.
RousselVYiFJauberteauMO. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun2000; 14: 259–265.
30.
BidotCJHorstmanLLJimenezJJ. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol2007; 7: 36–36.
31.
CuadradoMJKhamashtaMABallesterosA. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore)2000; 79: 57–68.
32.
IjdoJWConti-KellyAMGrecoP. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illness: MS or APS?Lupus1999; 8: 109–115.
33.
KarussisDLekerRRAshkenaziA. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?Ann Neurol1998; 44: 629–634.
34.
Mackworth-YoungCGHughesGRV. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry1985; 48: 185–185.
35.
HerranzMTRivierGKhamashtaMABlaserKUHughesGRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum1994; 37: 586–571.
36.
LiouHHWangCRChenCJ. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus1996; 5: 307–312.
37.
ShrivastavaADwivediSAggarwalAMisraR. Anti-cardiolipin and anti-beta2 glycoprotein 1 antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus2001; 10: 45–50.
38.
AppenzellerSCendesFCostallatLTL. Epileptic seizures in systemic lupus erythematosus. Neurology2004; 63: 1808–1812.
39.
SachseCLuthkeKHartungK. Significance of antibodies to cardiolipin in selected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. Rheumatol Int1995; 15: 23–29.
40.
FormigaFMitjavilaFPacMMogaI. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients. Lupus1997; 6: 486–486.
41.
VerrotDSan-MarcoMDravetC. Prevalence and significance of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med1997; 103: 33–37.
42.
PeltolaJTHaapalaAIsojarviJI. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new onset seizure disorders. Am J Med2000; 103: 33–37.
43.
SannaGBertolacciniMLCuadradoMJ. Neuropsychiatric manifestations in SLE: Prevalence and association with antiphospholipid antibodies. J Rheumatol2003; 30: 985–992.
